Your session is about to expire
← Back to Search
Device
Novel Spectacle Lenses for Myopia (EUCALYPTUS Trial)
N/A
Recruiting
Research Sponsored by SightGlass Vision, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Children 6 - 8 years of age (inclusive) at time of informed consent/assent
Be younger than 18 years old
Must not have
Current or prior use of bifocals, progressive addition spectacle lenses
Amblyopia in either eye
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a treatment to see how well it works for younger children. The study will look at results over time to predict how effective the treatment will be in the long term. The trial involves multiple sites to ensure accurate results.
Who is the study for?
This trial is for children aged 6-8 with mild to moderate near-sightedness (myopia) who have good vision with glasses and no more than a small difference in prescription between their eyes. They must be able to wear the study glasses at least 10 hours a day, not use contact lenses, and have no eye conditions or systemic diseases affecting vision.
What is being tested?
The study tests if special spectacle lenses can control worsening myopia in young children compared to regular single-vision lenses. It's a masked study where neither participants nor observers know which type of lens each child gets, randomly assigning kids into two groups equally.
What are the potential side effects?
Since this trial involves wearing different types of spectacle lenses, there are minimal side effects expected. However, some discomfort or adjustment issues may occur when switching from previous eyewear to the test spectacles.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My child is between 6 and 8 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I currently use or have used bifocals or progressive glasses.
Select...
I have a 'lazy eye'.
Select...
I have used treatments to control nearsightedness.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Spherical equivalent refraction
Secondary study objectives
Axial length
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Test Arm 2Experimental Treatment1 Intervention
Single vision, impact-resistant spectacle lenses
Group II: Test Arm 1Experimental Treatment1 Intervention
Single vision, impact-resistant spectacle lenses
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for myopia, or nearsightedness, include corrective lenses, orthokeratology, and pharmacological treatments. Corrective lenses, such as glasses or contact lenses, work by refocusing light directly onto the retina, thereby improving vision clarity.
Orthokeratology involves wearing specially designed rigid contact lenses overnight to temporarily reshape the cornea, reducing myopia during the day. Pharmacological treatments, like low-dose atropine eye drops, slow the progression of myopia by relaxing the eye's focusing mechanism and reducing eye elongation.
These treatments are crucial for myopia patients as they not only improve vision but also help in managing the progression of the condition, potentially reducing the risk of severe complications like retinal detachment or glaucoma.
New considerations for the clinical efficacy of old and new topical glaucoma medications.Investigating target refraction advice provided to cataract surgery patients by UK optometrists and ophthalmologists.The interactions of genes, age, and environment in glaucoma pathogenesis.
New considerations for the clinical efficacy of old and new topical glaucoma medications.Investigating target refraction advice provided to cataract surgery patients by UK optometrists and ophthalmologists.The interactions of genes, age, and environment in glaucoma pathogenesis.
Find a Location
Who is running the clinical trial?
SightGlass Vision, Inc.Lead Sponsor
10 Previous Clinical Trials
943 Total Patients Enrolled